Thymosin Alpha 1: the complete research guide.

Thymosin Alpha 1 sits in a strange position. It is approved in 35+ countries and has been used for decades in hepatitis B/C and cancer support. But the most rigorous recent trial, a 2025 Phase III in 1,106 sepsis patients, came back negative. Both facts are true, and the evidence picture requires holding them together.

What is Thymosin Alpha 1, exactly?

Thymosin Alpha 1 is a synthetic 28-amino-acid peptide. A chemical tweak on one end (an acetyl group) is required for activity. That tweak also makes the peptide technically tricky to manufacture correctly.

The molecule is identical to a natural thymic peptide first isolated by Allan Goldstein's lab in the 1970s. The pharmaceutical version appears in the literature under two names. Thymalfasin is the generic name. Zadaxin is the brand name, sold by SciClone Pharmaceuticals.

One framing point matters before going further. TA-1 is not the same as Thymosin Beta-4 (TB-4, or its research version TB-500). The two share only the word "thymosin." They were isolated from the same crude thymic mix in the 1970s, which is the only reason they sound related.

They are biologically unrelated. Different sequences. Different lengths. Different targets. Different functions. TB-4 is a 43-amino-acid tissue-repair peptide. TA-1 is a 28-residue immune modulator. Confusing them is one of the most common errors we see in peptide vendor catalogs.

How does it actually work?

The mechanism is not receptor-specific. TA-1 works through multiple parallel paths at once. A 2024 Frontiers in Medicine review by Garaci and colleagues argued for treating it as a "phenotypic drug." That means its effects emerge from broad immune engagement, not from binding a single target.

Here are the most replicated mechanisms:

• Toll-like receptor activation (TLR2 and TLR9). These are pattern-recognition sensors on immune cells. TA-1 turns them on, which boosts innate immune activation.
• T-cell function. CD4+ and CD8+ T cells mature and proliferate better in TA-1's presence. This matters most in older adults, where natural thymic peptide production has dropped.
• Plasmacytoid dendritic cell activation. A 2023 Immunity & Ageing paper from Espinar-Buitrago and colleagues showed TA-1 boosts activation markers (CD40, CD80, TIM-3) and TNF-α production in human cells.
• Cytokine rebalancing. TA-1 adjusts the mix of signals (IL-10, IFN-γ, inflammatory messengers) toward context-appropriate levels. It doesn't blanket-suppress or blanket-activate.
• Cell-death signaling. Pro-apoptotic in tumor cells. Anti-apoptotic in immune cells under stress. That context-dependence is part of why a single mechanism can't capture the drug.

Our honest read: TA-1 has several plausible mechanisms converging on broad immune effects. That explains both the wide range of indications it's been tried in (hepatitis, cancer support, sepsis, COVID, aging) and why the clinical results are mixed. A phenotypic drug can help in one setting and do nothing in another.

Immune support peptides

28 aa Acetylated Thymic origin

Thymosin Alpha 1 is on the Peptriva research-compound roadmap but is not currently stocked. For immune-adjacent research peptides we carry today, see the catalog — KPV is the closest in-stock analogue.

Browse research catalog

What's the international evidence base?

The TA-1 evidence base is unusually broad for a peptide that's not FDA-approved. Three decades of clinical use across 35+ countries. Anchored on hepatitis. Now expanding into cancer support and aging research.

Chronic hepatitis B and C. This is the foundational use case. Multiple randomized trials in the 1990s and 2000s tested TA-1 alone and combined with interferon. The aggregate evidence was enough to win approvals in China, Italy, and 30+ other jurisdictions. What's missing is a US regulatory path that took it to FDA approval.

Cancer immunotherapy support (the PRaG5.0 study). A 2024 BMJ Open protocol publication from Kong and colleagues described a multi-center study testing TA-1 alongside radiation, immunotherapy, and growth factors in advanced refractory cancers. The idea: TA-1 fixes the low-lymphocyte problem caused by cancer treatment. A 2023 Frontiers in Immunology review summarized the lung-cancer evidence. PRaG5.0 readouts will be the most consequential TA-1 data point in the next 24 months.

SARS-CoV-2 modulation. The 2023 Espinar-Buitrago paper showed TA-1 modulated COVID-specific T-cell responses, activated dendritic cells, and reduced inflammatory signals in cell culture. The authors proposed it as a candidate adjunct for elderly populations. This is lab work, not clinical trial data.

Immune support in aging. The reasoning is sound: aging shrinks the thymus, T-cell diversity drops, and TA-1 might compensate. But clinical evidence for healthspan benefits in older adults is sparse. None of the international approvals rest on this indication.

The TESTS Phase III sepsis trial

The 2025 TESTS trial in BMJ is the most important recent data point for TA-1. It's the kind of large, rigorous Phase III trial that immune-modulating peptides almost never get. And it produced a clearly negative result.

The headline numbers from the Wu et al. publication:

• Primary endpoint, 28-day all-cause mortality: 23.4% (TA-1) vs 24.1% (placebo). HR 0.99, P=0.93. Clearly negative.
• No secondary or safety endpoint differed significantly between arms.
• Subgroup signals: patients under 60 did worse on TA-1 (HR 1.67). Diabetes patients trended better (HR 0.58).
• Authors' verdict: "no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality in adults with sepsis."

The trial was big enough to detect a meaningful mortality difference. It didn't find one. The age-under-60 signal of worse outcomes is hypothesis-generating, not confirmed, but it complicates any framing of TA-1 as a harmless adjunct.

What TA-1 is actually used for

Active clinical use varies by country. Here's our honest ranking, ordered by strength of evidence:

• Chronic hepatitis B and C. The foundational use. Decades of experience. Strongest evidence base.
• Cancer immunotherapy support. Active research (PRaG5.0, lung-cancer reviews). Phase II/III data accumulating, not yet conclusive.
• Immune support in older adults. Mechanism is plausible. Clinical endpoint evidence is weak.
• Vaccine adjunct in immunocompromised patients. Biologically plausible. Investigational.
• COVID immune modulation. Cell-culture signals. Clinical translation incomplete.
• Sepsis support. Widely used historically. The 2025 TESTS trial was negative. The evidence has moved against TA-1 here.

What are the actual risks?

Our honest list:

• Well-tolerated. Injection-site reactions are the most common adverse event.
• No major safety signals in TESTS, even across 1,106 critically ill sepsis patients. Safety was equivalent to placebo.
• Subgroup harm signal in younger sepsis patients (age <60). Hypothesis-generating, not confirmed. But it warrants caution before extrapolating TA-1 to younger, immune-competent populations.
• Theoretical autoimmune concerns. Broad immune stimulation could in principle worsen autoimmune disease. Clinical experience doesn't strongly support this concern, but caution is reasonable.
• Cancer-context use requires physician supervision; investigational self-administration in cancer patients is outside the scope of standard clinical practice.
• Drug interactions with immunosuppressants, interferons, and cancer immunotherapies have been noted in the literature and warrant review in any supervised clinical context.
• Grey-market quality risk. Real Zadaxin from SciClone is manufactured to pharmaceutical standards. Grey-market vials aren't. The 28-residue acetylated peptide is technically demanding. Incomplete acetylation and sequence errors aren't visible without lab testing.

Regulatory status and WADA

TA-1's regulatory picture is the most internationally inconsistent of any peptide we cover. It's a fully approved drug in many countries and an unapproved research compound in the US. Same molecule. Same evidence base. Same manufacturer.

• FDA (US). Not approved for any indication. No NDA filed as of mid-2026.
• China (NMPA). Approved. Widely used in hepatitis B/C, cancer support, and historically sepsis.
• Italy. Approved as Zadaxin.
• 30+ other countries. Approved across Asia, Latin America, Eastern Europe, and the Middle East. India, Brazil, Mexico, Russia among them.
• EMA (EU). Not centrally approved. National approvals (notably Italy) exist on their own.
• WADA. Not explicitly listed on the Prohibited List as of 2026. Immune-modulating peptides are under ongoing scrutiny; sport-context status should be confirmed directly with WADA.

The cost gap between pharmaceutical and grey-market product

TA-1 pricing is bimodal. Pharmaceutical-grade Zadaxin runs in the hundreds of dollars per dose, with full hepatitis treatment courses in the thousands. Grey-market research-compound TA-1 in the US runs $40-$80 per 10 mg vial, about two orders of magnitude below pharmaceutical pricing.

The synthesis cost floor for a correctly acetylated 28-residue peptide is real. But the 100x price gap reflects regulatory status and supply chain more than manufacturing alone. That means three things for honest sourcing:

• Identity verification is essential for research use. A third-party CoA (Certificate of Analysis) confirming mass-spec identity for the acetylated 28-residue molecule is the minimum analytical standard for research-grade material.
• Grey-market TA-1 is not Zadaxin. Clinical claims from Zadaxin trials do not automatically transfer. The vial might be the same molecule. It might be partially acetylated. It might have sequence deletions. It might be something else entirely. Analytical verification is required to establish identity.
• Therapeutic use belongs in the regulated pathway. For hepatitis B/C, cancer support, or any indication where international evidence is strong, the appropriate pathway is physician-supervised use of the approved pharmaceutical, not unregulated research-compound material.

Peptriva research catalog

KPV in stock ≥99% pure Third-party CoA

TA-1 is on the roadmap; not currently stocked. For immune-adjacent research peptides currently in stock, see KPV in the research catalog — research-grade reference compound, COA per lot.

Browse research catalog

How should a researcher think about TA-1 in 2026?

We've spent time integrating the 2024 review, the 2025 TESTS Phase III, and the active cancer-support trials. Here's where we land: TA-1 is the most internationally validated peptide we cover outside the FDA-approved drugs. It has decades of real clinical use. And its most rigorous recent Phase III was clearly negative. Both facts have to coexist.

The right framing depends on the indication:

• Hepatitis B/C: substantial evidence. Pharmaceutical pathway through approved Zadaxin in jurisdictions that approve it.
• Cancer support: active research. PRaG5.0 readouts will be the next major signal.
• Sepsis: the 2025 TESTS Phase III was negative. The evidence has moved against TA-1 here, with a hypothesis-generating signal of worse outcomes in younger patients.
• Immune support / aging / COVID: mechanism is plausible. Clinical-endpoint evidence is sparse or absent. Use outside a trial setting is investigational.

Frequently asked questions

What is Thymosin Alpha 1?

It's a synthetic 28-amino-acid peptide identical to a natural thymic peptide first isolated by Allan Goldstein's lab in the 1970s. It's marketed as thymalfasin (generic name) and Zadaxin (brand name). Approved in 35+ countries, mostly for hepatitis B/C and cancer support.

Is TA-1 FDA-approved?

No. It's not FDA-approved in the US as of 2026, even though more than 35 other countries approve it, including China, Italy, India, Mexico, Brazil, and Russia. The US gap is unusual for a peptide with this much international clinical use.

What's the difference between Zadaxin and thymalfasin?

Same compound. Thymalfasin is the generic name. Zadaxin is the brand from SciClone Pharmaceuticals. When literature cites either, it means the pharmaceutical-grade 28-residue acetylated molecule.

How is TA-1 different from TB-500?

They're entirely different molecules. TA-1 is a 28-amino-acid immune modulator. TB-4 (of which TB-500 is the research analogue) is a 43-amino-acid tissue-repair peptide. They share only the "thymosin" prefix because they came from the same crude thymic mix in the 1970s. Sequences, targets, and functions are all unrelated. Conflating them is one of the most common errors in peptide vendor catalogs.

How does TA-1 work?

It's a broad immune modulator. The most replicated mechanisms are Toll-like receptor activation, support for T-cell maturation, activation of dendritic cells, and rebalancing of cytokine signals. The 2024 Garaci review reframes it as a "phenotypic drug." Its effects come from broad immune engagement, not from binding a single target.

What's the evidence for TA-1 in COVID-19 and long COVID?

Limited. The 2023 Espinar-Buitrago paper showed TA-1 modulated COVID-specific T-cell responses and activated dendritic cells in cell culture. The mechanism is plausible. But controlled clinical trials with published primary-endpoint data haven't happened as of 2026. The gap between cell-culture signal and clinical efficacy remains open.

What happened in the TESTS sepsis trial?

The TESTS Phase III trial was published in BMJ in 2025. 22 centers, 1,106 adults with sepsis, randomized to TA-1 or placebo every 12 hours for 7 days. The primary endpoint (28-day mortality) was negative: 23.4% with TA-1 vs 24.1% with placebo. The authors said there's no clear evidence TA-1 reduces sepsis mortality. A subgroup signal of worse outcomes in patients under 60 (HR 1.67) deserves further investigation. This is the largest and most rigorous TA-1 sepsis trial published to date.

How much does TA-1 cost?

The two markets are very different. Pharmaceutical-grade Zadaxin in approved jurisdictions runs hundreds of dollars per dose, with full treatment courses in the thousands. Grey-market research-compound TA-1 in the US runs $40-$80 per 10 mg vial, about 100x cheaper. The gap reflects regulatory status and supply chain, not manufacturing cost alone. Grey-market vials aren't the same product as Zadaxin and shouldn't be assumed to be without analytical verification.